COLLEGE STATION, TX — G-CON Manufacturing announces that it has successfully delivered and installed multiple PODs to Just – Evotec Biologics. The delivery advances the completion of the first J.POD manufacturing facility in North America, a one-of-a-kind cGMP biomanufacturing facility that features small intensified bioprocessing operations housed inside G-CON cleanroom PODs. The news comes after Evotec's announcement of Just – Evotec Biologics' expanded contract with the Department of Defense for the manufacturing of anti-SARS-CoV-2 monoclonal antibodies.

The J.POD facility features a flexible platform design that offers capacity scaling with additional PODs in the future and allows Just – Evotec Biologics to efficiently adapt and respond to changes in manufacturing demand for themselves and their clients.

"We feel honored and privileged to work on this true facility of the future," said Maik Jornitz, CEO of G-CON Manufacturing Inc. "The Just – Evotec Biologics team's vision is very much aligned with ours, and we enjoy the close work together for a common goal. Just – Evotec Biologics has adopted our cleanroom PODs as an integral component of their manufacturing technology platform, and we appreciate their trust."

"The arrival of the PODs built and delivered by the exceptional team at G-CON represents another milestone in the construction of our first J.POD facility in North America and a significant leap to accelerate drug development and expand biotherapeutic access to a greater patient population," said Jim Thomas, Executive Vice President and Global Head of Biotherapeutics at Just – Evotec Biologics.